The Covid-19 pandemic limited in-person business activities, but digital transformation strategies could help yield even higher profits for local pharmaceutical and biotech companies, an industry official said.James Choi, senior vice president and chief information and marketing officer at Samsung B
Cytiva, a global life science company, said it was reviewing Korea as one of the candidates for Asian production site as part of an expansion of regional manufacturing facilities, emphasizing the importance of supply chain sustainability.Cytiva Korea’s Strategy and Marketing Leader Kim Ki-hoon parti
Messenger RNA (mRNA) emerged as a next-generation biopharmaceutical technology, as it is expected to prevent and treat various types of diseases.However, rather than rushing to develop mRNA vaccines as researchers have recently done to fight Covid-19, researchers should consider “many factors” from
GC LabCell and GC Cell announced that their merger plan would go as planned, drawing attention to how it will affect the cell therapy market.In a regulatory filing, the two companies said that their shareholders approved the merger at a meeting on Monday.The merger date is set for Nov. 1, and the su
Samsung Bioepis said it has confirmed the safety and long-term efficacy profiles of Ontruzant (ingredient: trastuzumab), a biosimilar of cancer medicine trastuzumab, in a five-year follow-up study.The company will present the results of its long-term study comparing Ontruzant ) and reference medicin
Samsung Bioepis said it confirmed its Lucentis (ingredient: ranibizumab) biosimilar, Byooviz, as an effective and valuable option for patients with neovascular age-related macular degeneration (nAMD) in phase 3 clinical trial.The new study results will be presented at an online meeting hosted by the
Woojung Bio said it would open the nation’s first privately-led cluster for new drug development late in September.The company recently teamed up with Ahn Hae-young, CEO of Ahn Bio Consulting, who previously worked as division deputy director at the FDA.The collaboration raised anticipation for a su
Genome & Company, an immunotherapy developer, has taken the first to jump into the CDMO industry by acquiring a U.S. microbiome company, List Biological Laboratory (List Labs).At an online news conference on Wednesday, the company presented its mid-to-long-term vision of becoming a fully integrated
As the U.S. plans to expand the global Covid-19 vaccine supply chain, Korean contract development and manufacturing organizations (CDMOs) should grab an opportunity to attract U.S. investment, a local biotech industry group said.Quoting White House Covid-19 advisor Jeff Zients, Korea Biotech Industr
Hanall Biopharma is one of the most frequently mentioned Korean drugmakers when analysts forecast the arrival of a global blockbuster drug. In developing autoimmune disease treatment candidate HL161(batoclimab), there are many ongoing clinical trials of batoclimab by partners in the U.S. and China t
Cellid released the results of a phase 2a trial of Covid-19 vaccine candidate AdCLD-CoV19.The company disclosed cases of the adverse events partially and said the middle dose group and the high dose group did not demonstrate a statistically significant difference in neutralizing antibody titer.The c
Boryung Pharmaceutical said Wednesday that it has launched Onbevzi, a biosimilar for Avastin (Ingredient: bevacizumab) developed by Samsung Bioepis in Korea.The launch comes after Boryung acquired exclusive sales rights in Korea for Onbevzi from Samsung in May of this year. According to the company,
The Korea Exchange granted a one-year grace period for Kolon TissueGene, delaying the decision whether to delist the company from the Kosdaq market.Last year, the government revoked the permit for the company’s gene therapy Invossa-K over mislabeling an ingredient and falsely reporting it to the reg
Eyegene said it received the regulatory nod for a local clinical trial of an mRNA Covid-19 vaccine.The company uses its technology, different from mRNA Covid-19 vaccines by Moderna or Pfizer/BioNTech. As a result, industry watchers are paying attention to whether Eyegene can commercialize the vaccin
SK Bioscience has started administering Covid-19 vaccine candidate GBP510, jointly developed with the Institute for Protein Design (IPD) at the University of Washington, in phase 3 clinical trials.The company’s clinical trials are the first domestic phase 3 study of the Covid-19 vaccine approved by
CancerRop, a molecular diagnostics company, said it would raise capital by issuing new shares worth 20 billion won ($17.1 million) to Hanmi Science through a third-party allotment.With the new shares, Hanmi Science CEO Lim Jong-yoon will become the largest stakeholder of CancerRop. Hanmi Science rec
A joint research team has succeeded in identifying the human development process using whole-genome sequencing technology, Kyungpook National University Hospital (KNUH) said Friday.The study was published in the online edition of Nature on Aug. 25.Professor Oh Ji-won of Kyungpook National University
The Korea National Enterprise for Clinical Trials (KONECT) said Wednesday that it has agreed with SK Bioscience to help recruit phase 3 clinical trial participants for the first Korean-made Covid-19 vaccine.Under the agreement, the two sides will share the information on the agency and research team
GenNBio said Wednesday it has submitted an investigational new drug (IND) application to conduct the phase 1 trial of the xenotransplantation of germ-free pigs’ Langerhans islets to diabetes patients to the Ministry of Food and Drug Safety.In August last year, GenNBio applied for IND to conduct an i
Samsung Biologics has recently won the cell line patent invalidation trial filed in China against the Swiss multinational biotech company, Lonza, it was learned.In January, the company filed a trial for invalidation of cell line-related patents with China's National Intellectual Property Administrat